KCT0003207Recruiting未知
Effect of Crataegus pinnatifida Bunge extract on the Safety and Memory Improvement ; A Randomized, Double-blind, Placebo-Controlled Clinical Trial
OKCHUNDANG0 sites70 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 70
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional Study
Eligibility Criteria
- Ages
- 45(Year) to 65(Year) (—)
- Sex
- All
Inclusion Criteria
- •1. Males and females 45 =age = 65
- •2. Those with elementary school or higher education
- •3. Subjects whose MQ(Memory Quotient) score in Rey-Kim memory test is 70 or more, but less than 120.
- •4. Subjects who after listening carefully and fully understanding this clinical trial, has decided to participate voluntarily and has agreed in writing to observe the cautions.
- •5. Subjects who are possible to follow up during the trial period.
- •6. Subjects whose depression or anxiety subscale score in HADS(Hopital Anxiety and Depression Scale) is less than 8.
- •7. Subjects who doesn’t meet the exclusion criteria
Exclusion Criteria
- •1. Subjects with physical diseases which can affect memory such as neurodegenerative diseases like dementisa, Parkinson disease, traumatic brain injury, stroke.
- •2. Subjects who have taken any medicines or dietary supplements which can affect memory within 4 weeks.
- •3. Subjects who have allergic reaction or hypersensitive reaction to experimental supplement.
- •4. Subjects who have hepatoma, liver cirrhosis, chronic renal failure, congestive heart failure.
- •5. Subjects who have been taking antihistaminic agent, nonsteroidal antiinflammatory drug, steroid, antibiotics, decongestant.
- •6. Subjects who have been taking any medicine to treat hyperthyroidism or hypothyroidism within 1 year.(Subjects who investigators decided to be possible to participate to this trial can be involved.)
- •7. Subjects who have severe migraine, thromboembolism, cerebrovascular disease, myocardial infarction, unstable angina pectoris, or PTCA within 1 year.
- •8. Subjects who have mental disorders like depression, anxiety disorders, or been taking any antidepressants, antipsychotics agents.
- •9. Subjects who have uncontrolled diabetes mellitus. (FBT = 80mg/dL or Subjects who started new hypoglycemic agents withing the last 3 months)
- •10. Subjects who have history of drug or alcohol dependency or abuse.
- •11. ALT(Alanine transaminase) or AST(Aspartate transaminase) > 2.5 times compared to the normal upper limit in research institute.
- •12. Creatinine > 2.5 times compared to the normal upper limit in research institute.
- •13. Subjects who participated in another clinical study in the last 30 days or plan to participate in another clinical study.
- •14. Subjects who are pregnancy, breast feeding, or females of childbearing potential who are not practicing acceptable pregnancy prevention methods.
- •15. Subjects who are institutionalized in group facilities like social welfare organs.
- •16. Subjects who have difficulty of communication or writing due to visual, auditory, physical impairment.
- •17. Subjects who are not appropriate by investigator’s decision.
Investigators
Similar Trials
Recruiting
Phase 3
Effect of Crataegus Monogyna in hypertension and associated sleep disorderIRCT20180225038859N1Zanjan University of Medical Sciences60
Completed
Not Applicable
Effect of Crataegus oxycantha on gastroesophageal reflux disease (GERD) symptomsGastroesophageal Reflux Disease.Gastro-oesophageal reflux disease without oesophagitisIRCT2013081314345N1School of Traditional Medicine, Tehran University of Medical Sciences80
Completed
Phase 4
A study to compare pomegranate fruit peel powder converted into gel and commercially available gel in the treatment of disease called oral lichen planusCTRI/2018/12/016523Dr Mahalakshmi V40
Completed
Phase 4
This is a study to know the effectiveness of pomegranate (punica granatum) peel extract in the treatment of denture stomatitisCTRI/2018/02/011660Dr V Mahalakshmi50
Recruiting
Phase 3
Evaluation the effect of Punica granatum L. ointment in burn woundIRCT20180609040016N4Shiraz University of Medical Sciences30